Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IOBT IO Biotech Inc
- Stocks
- Healthcare
- NASDAQ: IOBT
Price (delayed)
$1.45
Market cap
$95.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.49
Enterprise value
$60.2M
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins,
Highlights
IO Biotech's debt has decreased by 24% YoY and by 8% QoQ
The company's EPS rose by 17% YoY but it fell by 2.8% QoQ
The quick ratio has dropped by 81% year-on-year and by 34% since the previous quarter
IO Biotech's equity has shrunk by 77% YoY and by 44% QoQ
Key stats
What are the main financial stats of IOBT
Market
Valuations
Earnings
Shares outstanding
65.88M
Market cap
$95.53M
Enterprise value
$60.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.62
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$97.56M
Net income
-$98.46M
EBIT
-$97.28M
EBITDA
-$96.42M
Free cash flow
-$80.55M
Per share
Balance sheet
Liquidity
EPS
-$1.49
EPS diluted
-$1.49
Free cash flow per share
-$1.22
Book value per share
$0.4
Revenue per share
$0
TBVPS
$0.69
Total assets
$45.74M
Total liabilities
$19.31M
Debt
$1.76M
Equity
$26.42M
Working capital
$24.06M
Debt to equity
0.07
Current ratio
2.32
Quick ratio
2.03
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-125.1%
Return on equity
-162.6%
Return on invested capital
N/A
Return on capital employed
-354.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IOBT stock price
How has the IO Biotech stock price performed over time
Intraday
-3.97%
1 week
21.85%
1 month
42.16%
1 year
20.83%
YTD
57.61%
QTD
33.03%
Financial performance
How have IO Biotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$97.56M
Net income
-$98.46M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 11% YoY and by 3.1% from the previous quarter
The company's operating income fell by 4.1% YoY and by 2.5% QoQ
Price vs fundamentals
How does IOBT's price correlate with its fundamentals
Growth
What is IO Biotech's growth rate over time
Valuation
What is IO Biotech stock price valuation
P/E
N/A
P/B
3.62
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 17% YoY but it fell by 2.8% QoQ
The stock's price to book (P/B) is 169% more than its last 4 quarters average of 1.4
IO Biotech's equity has shrunk by 77% YoY and by 44% QoQ
Efficiency
How efficient is IO Biotech business performance
The return on equity has dropped by 135% year-on-year and by 41% since the previous quarter
IOBT's return on assets has dropped by 101% year-on-year and by 30% since the previous quarter
Dividends
What is IOBT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IOBT.
Financial health
How did IO Biotech financials performed over time
IO Biotech's total assets is 137% higher than its total liabilities
The quick ratio has dropped by 81% year-on-year and by 34% since the previous quarter
The current ratio has dropped by 79% year-on-year and by 30% since the previous quarter
IO Biotech's debt is 93% lower than its equity
IO Biotech's equity has shrunk by 77% YoY and by 44% QoQ
The debt to equity has surged by 75% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.